Healthcare
Telix Pharmaceuticals Limited(TLPPF)
Live Price
Offline$10.04
+0.00% today
1Y Change
-43.94%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $5.28B
- Revenue Growth
- +59.1%
- EPS Growth
- -121.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telix Pharmaceuticals Limited (TLPPF) is a Healthcare stock with a market cap of $5.28B and listed on OTC. The stock last traded around $10.04 and down 43.9% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +59.1%, EPS growth of -121.8%, a dividend yield of 0.0%. What stands out right now is revenue +59.1%, EPS -121.8%, free cash flow -1051.3% with operating margin 2.1% and ROIC 1.8%. Valuation sits in the middle of the pack at price/sales 4.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TLPPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+59.1% vs +7.6% peer median
Operating Margin
Below sector median
+2.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 19, 2026 with an EPS surprise of -135.4% and a revenue surprise of -1.2%.
The operating picture looks softer than before
Revenue is at +59.1% and EPS is at -121.8%, with operating margin around 2.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 20, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 19, 2026 | -135.4% | +15.3% | +1.2% | +26.2% |
2025 Aug 20, 2025 | -105.1% | +9.6% | +10.0% | -18.8% |
2025 Feb 20, 2025 | -24.2% | -10.4% | -5.7% | -4.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLPPF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TLPPF Max Drawdown
-63.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TLPPF and SPY.
Company Overview
Telix Pharmaceuticals Limited
Other OTC
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
- Leadership
- Christian Behrenbruch
- IPO Date
- Jul 25, 2019
- Employees
- 415
- Street Address
- 55 Flemington Road
- Mailing
- North Melbourne, VIC, 3051
- Region
- North Melbourne, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 3093 3897
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 157.9
- Price/Sales
- 4.3
- Price/Book
- 8.5
Growth
- Revenue
- +59.1%
- EPS
- -121.8%
- Free Cash Flow
- -1051.3%
Profitability
- Gross Margin
- 50.8%
- Operating Margin
- 2.1%
- Net Margin
- -0.9%
- ROE
- -2.1%
- ROIC
- 1.8%
Balance Sheet
- Debt/Equity
- 1.26
- Current Ratio
- 1.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.